A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-22
DOI
10.1038/s41416-021-01476-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR
- (2021) Shenlan Mao et al. MOLECULAR CANCER THERAPEUTICS
- Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development
- (2021) Fumiya Moribe et al. PLoS One
- SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
- (2021) Ukhyun Jo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Awakening of SCHLAFEN 11 by immunohistochemistry: a new biomarker predicting response to chemotherapy
- (2021) Reinhard Buettner VIRCHOWS ARCHIV
- Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers
- (2021) Tsuyoshi Takashima et al. BRITISH JOURNAL OF CANCER
- SLFN11 inactivation induces proteotoxic stress and sensitizes cancer cells to ubiquitin activating enzyme inhibitor TAK-243
- (2021) Yasuhisa Murai et al. CANCER RESEARCH
- Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression
- (2020) Daniel Rathkey et al. Journal of Thoracic Oncology
- SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy
- (2020) Vincenza Conteduca et al. MOLECULAR CANCER THERAPEUTICS
- BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
- (2020) Florence Coussy et al. Science Translational Medicine
- EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
- (2020) Stephanie Lheureux et al. CLINICAL CANCER RESEARCH
- Gene Expression Regulation of the Type I Interferon‐Induced Protein Schlafen 11
- (2020) Andre Raymundo Borrego et al. FASEB JOURNAL
- Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo
- (2020) Anke E. M. van Erp et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq
- (2020) Tsuyoshi Takashima et al. VIRCHOWS ARCHIV
- Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress
- (2020) Junko Murai et al. Cell Reports
- cGAS-STING, an important pathway in cancer immunotherapy
- (2020) Minlin Jiang et al. Journal of Hematology & Oncology
- Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets
- (2020) Julia Krushkal et al. Clinical Epigenetics
- A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies
- (2020) Sara M. Federico et al. EUROPEAN JOURNAL OF CANCER
- SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures
- (2020) Camille Tlemsani et al. Cell Reports
- The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
- (2020) Niamh Coleman et al. BRITISH JOURNAL OF CANCER
- SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
- (2020) Claudia Winkler et al. BRITISH JOURNAL OF CANCER
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
- (2019) Riccardo Mezzadra et al. PLoS One
- PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
- (2019) Patrick G. Pilié et al. CLINICAL CANCER RESEARCH
- Schlafen 11 Restricts Flavivirus Replication.
- (2019) Federico Valdez et al. JOURNAL OF VIROLOGY
- Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
- (2019) Junko Murai et al. PHARMACOLOGY & THERAPEUTICS
- Correction to: Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer
- (2019) Edoardo Isnaldi et al. BREAST CANCER RESEARCH AND TREATMENT
- Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer
- (2019) Edoardo Isnaldi et al. BREAST CANCER RESEARCH AND TREATMENT
- The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination–Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
- (2019) Laetitia Marzi et al. CLINICAL CANCER RESEARCH
- Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
- (2019) Anna F. Farago et al. Cancer Discovery
- Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy
- (2019) Kevin Shee et al. PLoS One
- Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?
- (2019) Jose M. Pacheco et al. Cancer Discovery
- Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11)Expression with Class I Histone Deacetylase Inhibitors
- (2018) Sai-Wen Tang et al. CLINICAL CANCER RESEARCH
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- SLFN11 Blocks Stressed Replication Forks Independently of ATR
- (2018) Junko Murai et al. MOLECULAR CELL
- DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs
- (2018) Manqing Li et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
- (2017) Alberto Ballestrero et al. Journal of Translational Medicine
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer
- (2017) Tao He et al. Epigenomics
- Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
- (2017) C. Allison Stewart et al. Oncotarget
- Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis
- (2016) D. De Ruysscher et al. ANNALS OF ONCOLOGY
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Order from clutter: selective interactions at mammalian replication origins
- (2016) Mirit I. Aladjem et al. NATURE REVIEWS GENETICS
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Regulation and Function of Cdt1; A Key Factor in Cell Proliferation and Genome Stability
- (2016) Pedro Pozo et al. Genes
- High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment
- (2015) Yanhong Deng et al. BMC CANCER
- Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
- (2015) M. H. Kang et al. CLINICAL CANCER RESEARCH
- SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma
- (2015) S.-W. Tang et al. CLINICAL CANCER RESEARCH
- Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity
- (2015) Fabricio G. Sousa et al. DNA REPAIR
- SLFN11 inhibits checkpoint maintenance and homologous recombination repair
- (2015) Y. Mu et al. EMBO REPORTS
- Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase
- (2015) Rémi Buisson et al. MOLECULAR CELL
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
- (2015) Vanesa Nogales et al. Oncotarget
- Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan
- (2014) Li Tian et al. ANTI-CANCER DRUGS
- PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
- (2013) J.-m. Lee et al. ANNALS OF ONCOLOGY
- The Schlafen Family of Proteins and Their Regulation by Interferons
- (2013) Evangelos Mavrommatis et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11
- (2012) Manqing Li et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Schlafen 11 naturally blocks HIV
- (2012) Mina Razzak Nature Reviews Urology
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
- (2012) G. Zoppoli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nucleotide Deficiency Promotes Genomic Instability in Early Stages of Cancer Development
- (2011) Assaf C. Bester et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Promiscuous partnerships in Ewing's sarcoma
- (2011) Savita Sankar et al. Cancer Genetics
- Role of Interferon α (IFNα)-inducible Schlafen-5 in Regulation of Anchorage-independent Growth and Invasion of Malignant Melanoma Cells
- (2010) Efstratios Katsoulidis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence
- (2009) Olivia Bustos et al. GENE
- Subcellular localization of the Schlafen protein family
- (2008) Brent Neumann et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started